Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Erin H Jensen"'
Autor:
Marin H. Kollef, Jean-François Timsit, Ignacio Martin-Loeches, Richard G. Wunderink, Jennifer A. Huntington, Erin H. Jensen, Brian Yu, Christopher J. Bruno
Publikováno v:
Critical Care, Vol 26, Iss 1, Pp 1-13 (2022)
Abstract Background Ceftolozane/tazobactam, a combination antibacterial agent comprising an anti-pseudomonal cephalosporin and β-lactamase inhibitor, is approved for the treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/
Externí odkaz:
https://doaj.org/article/c38430b8642f45b995171dd794db572c
Autor:
Jean-François Timsit, Jennifer A. Huntington, Richard G. Wunderink, Nobuaki Shime, Marin H. Kollef, Ülo Kivistik, Martin Nováček, Álvaro Réa-Neto, Ignacio Martin-Loeches, Brian Yu, Erin H. Jensen, Joan R. Butterton, Dominik J. Wolf, Elizabeth G. Rhee, Christopher J. Bruno
Publikováno v:
Critical Care, Vol 25, Iss 1, Pp 1-14 (2021)
Abstract Background Ceftolozane/tazobactam is approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at double the dose approved for other infection sites. Among nosocomial pneumonia subtypes, ventilated HAB
Externí odkaz:
https://doaj.org/article/b8ee6048ea624162b18dfef8acdeaed8
Autor:
Ignacio Martin-Loeches, Andrew F Shorr, Marin H Kollef, Jiejun Du, Maria C Losada, Amanda Paschke, C Andrew DeRyke, Michael Wong, Erin H Jensen, Luke F Chen
Publikováno v:
Open Forum Infectious Diseases.
Background In the RESTORE-IMI 2 trial, imipenem/cilastatin/relebactam (IMI/REL) was noninferior to piperacillin/tazobactam in treating hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. This post hoc analysis was conduct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ac282514b3de02b391630c47b967cdf
https://doi.org/10.1093/ofid/ofad225
https://doi.org/10.1093/ofid/ofad225
Autor:
Ignacio, Martin-Loeches, Jean-François, Timsit, Marin H, Kollef, Richard G, Wunderink, Nobuaki, Shime, Martin, Nováček, Ülo, Kivistik, Álvaro, Réa-Neto, Christopher J, Bruno, Jennifer A, Huntington, Gina, Lin, Erin H, Jensen, Mary, Motyl, Brian, Yu, Davis, Gates, Joan R, Butterton, Elizabeth G, Rhee
Publikováno v:
J Antimicrob Chemother
Objectives In the ASPECT-NP trial, ceftolozane/tazobactam was non-inferior to meropenem for treating nosocomial pneumonia; efficacy outcomes by causative pathogen were to be evaluated. Methods Mechanically ventilated participants with hospital-acquir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffab12e476c1f960bad5a063e8f565e9
https://doi.org/10.1093/jac/dkab494
https://doi.org/10.1093/jac/dkab494
Autor:
David L Paterson, Matteo Bassetti, Mary Motyl, Matthew G Johnson, Mariana Castanheira, Erin H Jensen, Jennifer A Huntington, Brian Yu, Dominik J Wolf, Christopher J Bruno
Publikováno v:
The Journal of antimicrobial chemotherapy. 77(9)
Background After the MERINO trial with piperacillin/tazobactam, the efficacy of β-lactam/tazobactam combinations in serious infections involving extended-spectrum β-lactamase (ESBL)-producing pathogens merits special evaluation. Objectives To furth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c3a15bd369e1e183b581c7b522cdb9d
https://pubmed.ncbi.nlm.nih.gov/35781341
https://pubmed.ncbi.nlm.nih.gov/35781341
Autor:
Yoav Golan, Herbert L DuPont, Fernando Aldomiro, Erin H Jensen, Mary E Hanson, Mary Beth Dorr
Publikováno v:
Open Forum Infectious Diseases
Renal impairment is not a consistently cited risk factor for recurrentWe pooled data from 2 randomized, double-blind, placebo-controlled, multicenter, phase 3 clinical trials conducted in participants receiving bezlotoxumab or placebo infusion during
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d3b7e29e0c9e2e854214457fde549ea
https://doi.org/10.1093/ofid/ofaa629
https://doi.org/10.1093/ofid/ofaa629
Autor:
Erin H. Jensen, Adam B. Polis, Philippe Brudi, Amy O. Johnson-Levonas, John R. Guyton, Michel Farnier
Publikováno v:
Journal of Clinical Lipidology. 6:289-290
s 289 12 in lipoprotein particle concentrations and size. The median change in LDL particle concentration (LDL-P) was 2505.0 nmol/L for pitavastatin and 2376.0 nmol/L for pravastatin (treatment difference 5 2127.0 nmol/L; P , .001), with no significa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b8215ef61b6c009647fada1025e6be6
https://doi.org/10.1016/j.jacl.2012.04.069
https://doi.org/10.1016/j.jacl.2012.04.069
Autor:
Samuel E. Wilson, Robin S. Turpin, Ritesh N. Kumar, Kamal M.F. Itani, Erin H. Jensen, James M. Pellissier, Murray A. Abramson
Publikováno v:
Surgical Infections; Jun2008, Vol. 9 Issue 3, p349-356, 8p
Publikováno v:
Surgical Infections; Apr2008, Vol. 9 Issue 2, p131-137, 7p
Publikováno v:
Surgical Infections; Feb2007, Vol. 8 Issue 1, p15-28, 14p